@article{ac0532159b83447187c3f2936455f15a,
title = "The Principles and Practice of PARP Inhibitor Therapy",
author = "Yap, {Timothy A.} and Coleman, {Robert L.}",
note = "Funding Information: Disclosures: T.A.Y.: Research support (to institution): AstraZeneca, Artios, Bayer, Beigene, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Repare, Regeneron, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals; consultancies: Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian and Zai Labs. T.A.Y. is principal investigator of a Department of Defense grant (OC200482), NIH/NCI R01 grant (1R01CA255074-01), and V Foundation Scholar Grant (VC2020-001). R.L.C.: grants: Clovis Oncology, AstraZeneca, Gateway Foundation, Janssen, Judy Reis/Albert Pisani, MD, Ovarian Cancer Research Fund, Merck, National Institutes of Health, Roche/Genentech, and V-Foundation; has served as an advisor to Clovis Oncology, Agenus, AstraZeneca, GamaMabs, Genmab, Janssen, OncoQuest, Pfizer (Medivation), Regeneron, Roche/Genentech, and Tesaro. Funding Information: T.A.Y. acknowledges the MD Anderson Cancer Center Support grant (NIH/NCI P30 CA016672).",
year = "2021",
month = dec,
day = "27",
doi = "10.1097/PPO.0000000000000563",
language = "English (US)",
volume = "27",
pages = "430--431",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",
}